Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Biopharmaceuticals and Conventional Drugs: Clinical Success Rates

Bio/Technology volume 10, pages 521–525 (1992)Cite this article

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. The NDA Pipeline (F-D-C Reports, Inc., Chevy Chase, MD, 1983-1991.

  2. Pharma Projects (I. Hutton, ed., PJB Publications Ltd., 1984-1991).

  3. Wardell, W.M., Hassar, M., Anavekar, S.N., and Lasagna, L. 1978. The rate of development of new drugs in the United States, 1963 through 1975. Clin. Pharmacol. Ther. 24: 133–145.

    Article  CAS  Google Scholar 

  4. Mattison, N., Trimble, A.G., and Lasagna, L. 1988. New drug development in the United States, 1963 through 1984. Clin. Pharmacol. Ther. 43: 290–301.

    Article  CAS  Google Scholar 

  5. A detailed description of our success rate calculations and a chart illustrating clinical development for all biotechnology products of the 1980s are available from the authors upon request.

  6. Guide to the Excerpta Medica Classification and Indexing System (Excerpta Medica, Amsterdam, 2nd edition, 1984).

  7. Sheck, L., Cox, C., Davis, H.T., Trimble, A.G., Wardell, W.M., and Hansen, R. 1984. Success rates in the United States drug development system. Clin. Pharmacol. Ther. 36: 574–583.

    Article  CAS  Google Scholar 

  8. Tucker, S., Blozan, C., and Coppinger, P. 1988. The outcome of research on new molecular entities commencing clinical research in the years 1976-1978. OPE (Office of Planning and Evaluation, Food and Drug Administration) Study 77.

Download references

Author information

Authors and Affiliations

  1. the Center for the Study of Drug Development, Tufts University, Boston, MA

    Brigitta Bienz-Tadmor, Patricia A. DiCerbo & Louis Lasagna

  2. the department of electrical and computer engineering, Northeastern University, Boston, MA

    Gilead Tadmor

Authors
  1. Brigitta Bienz-Tadmor
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patricia A. DiCerbo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gilead Tadmor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Louis Lasagna
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bienz-Tadmor, B., DiCerbo, P., Tadmor, G. et al. Biopharmaceuticals and Conventional Drugs: Clinical Success Rates. Nat Biotechnol 10, 521–525 (1992). https://doi.org/10.1038/nbt0592-521

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0592-521

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing